<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have recently shown that long-term, but not <z:hpo ids='HP_0011009'>acute</z:hpo>, treatment with <z:chebi fb="32" ids="30145">lithium</z:chebi> robustly protects cultured <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> neurons against excitotoxicity mediated by <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptors </plain></SENT>
<SENT sid="1" pm="."><plain>Since <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor over-excitation has been strongly implicated in the ischemic brain injury, we examined the effects of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="32" ids="30145">lithium</z:chebi> treatment on neurological deficit and brain <z:mpath ids='MPATH_124'>infarct</z:mpath> induced by occlusion of the left middle cerebral artery in rats </plain></SENT>
<SENT sid="2" pm="."><plain>Subcutaneous injection of <z:chebi fb="5" ids="48607">LiCl</z:chebi> for 16 days significantly improved neurological deficits, including <z:mp ids='MP_0001504'>abnormal posture</z:mp> and <z:hpo ids='HP_0002301'>hemiplegia</z:hpo>, measured 24 h after <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Importantly, the size of ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> was reduced by 56% after <z:chebi fb="32" ids="30145">lithium</z:chebi> pretreatment </plain></SENT>
<SENT sid="4" pm="."><plain>These results raise the possibility that <z:chebi fb="32" ids="30145">lithium</z:chebi> may be useful for reducing focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced brain damage and <z:hpo ids='HP_0000707'>neurological abnormalities</z:hpo> </plain></SENT>
</text></document>